VIVS — VivoSim Labs Balance Sheet
0.000.00%
- $5.79m
- -$0.89m
- $0.14m
- 20
- 27
- 38
- 17
Annual balance sheet for VivoSim Labs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 37.4 | 28.7 | 16 | 2.9 | 11.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | 0.152 | 0.033 | 0.03 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 38.4 | 29.5 | 17 | 3.94 | 12.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.381 | 2.81 | 2.61 | 1.97 | 1.29 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 39.9 | 33.3 | 20.3 | 6.35 | 14.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.721 | 1.38 | 3.67 | 1.86 | 3.74 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.721 | 3.09 | 4.98 | 2.75 | 4.16 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 39.2 | 30.2 | 15.3 | 3.6 | 10.5 |
| Total Liabilities & Shareholders' Equity | 39.9 | 33.3 | 20.3 | 6.35 | 14.7 |
| Total Common Shares Outstanding |